Akeso Biopharma focuses on discovering and developing innovative biologics with international intellectual rights for the treatment of a broad spectrum of diseases. It is also co-developing antibody drugs with strategic partners and collabortors.
Akeso Biopharma, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/akeso-pharmaceuticals” connections=”true” suffix=””]
Akesobio proprietary platforms includes efficient expression platform of mammalian cells. Rapid hybridoma generation with tolerance breaking technologies, 3D humanization and optimization.
In Nov 2015, Akeso out liscence its immune checkpoint blocking antibody – AK107 to MSD China (known as Merck in the United States and Canada) to research, develop and commercialize. Under the terms, Akeso shall receive up to $200 Mn in development and commercialization milestone payments.from MSD.
In July 2015, Akeso successfully raised approx $20Mn in Series A private placement led by Shenzhen Capital Group Co., Ltd, Zhongshan Pheaton Capital Management, L.P., Shanghai CCB Capital Co., Ltd, and Shenzhen Qianhai Xinnuo Capital Co., Ltd.
In Aug 2017, Akeso further raised $45Mn in series B financing round led by ShenZhen GTJA Investment Group. The other investors included in the investment were Qianhai Fund of Funds, Shenzhen Capital Group and TriWise Capital.